Baidu
map

10大静脉血栓与抗凝误区

2018-12-20 佚名 深静脉血栓

误区1伤后与术后抗凝过晚 伤后24h后血液高凝达到高峰,术后6h 纤溶达到高峰,并持续到术后18h,建议术后6h后尽早开始抗凝


误区1伤后与术后抗凝过晚

伤后24h后血液高凝达到高峰,术后6h 纤溶达到高峰,并持续到术后18h,建议术后6h后尽早开始抗凝

误区2不认真筛查禁忌症,不详细问病史

建议对所有进行抗凝治疗的病人,详细询问头颅的外伤史,必要时进行CT检查

误区3出院后不扩展抗凝

术后患者发生小腿肌间静脉血栓,但并未进行扩展抗凝,导致血栓卷土重来,患者再次住院。建议骨科大手术患者,术后延长抗凝预防至术后35天,而不仅是10-14天。如果术后发生静脉血栓,持续抗凝治疗至少3个月。

误区4只看腿部血栓,不看腹腔血栓

腹腔静脉血栓与下肢深静脉血栓的危害一样,栓子一旦脱落,可能导致肺栓塞,因此临床中应警惕下腔静脉血栓(如腹膜后静脉血栓)的发生。

误区5不了解下肢DVT有两种生长方式

1)高凝状态形成血栓,一般从小腿肌间静脉血栓生长,逐渐向上蔓延。

2)类似骨折的直接暴力导致血栓,一般发生在创伤部位

误区6下肢静脉血栓的归宿

下肢深静脉血栓即使经过积极抗凝治疗后,血栓也不会很快消失,而是在抗凝药物的作用及自身纤溶系统的作用下由大栓子变成小栓子,小栓子可能会随血管顺流而上,游走到肺部形成肺栓塞。

误区7肌间静脉不用管

很多人认为发生肌间静脉血栓后无需抗凝治疗,但是研究表明1.6%的肌间静脉血栓会发生PE。因此对于肌间静脉血栓同样应评估抗凝获益与风险,建议只要有血栓发生,就应该进行抗凝治疗。

误区8误以为左右两条腿发生DVT概率一样

左下肢血栓发生率高,右下肢血栓死亡率高

误区9不敢用华法林,盲目使用阿司匹林

不能用阿司匹林替代抗凝药进行静脉血栓的治疗,推荐应用低分子肝素进行急性期治疗后,改为华法林作为静脉血栓的长期治疗用药。

误区10房颤患者不能正确抗凝

建议积极抗凝治疗预防房颤导致的栓塞事件。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1955408, encodeId=17fb195540843, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 31 01:06:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697822, encodeId=3f6c169e82228, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Mar 23 20:06:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308859, encodeId=5c6b13088599e, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Dec 22 11:06:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355961, encodeId=4003355961bd, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Thu Dec 20 22:46:12 CST 2018, time=2018-12-20, status=1, ipAttribution=)]
    2019-07-31 xue8602
  2. [GetPortalCommentsPageByObjectIdResponse(id=1955408, encodeId=17fb195540843, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 31 01:06:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697822, encodeId=3f6c169e82228, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Mar 23 20:06:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308859, encodeId=5c6b13088599e, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Dec 22 11:06:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355961, encodeId=4003355961bd, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Thu Dec 20 22:46:12 CST 2018, time=2018-12-20, status=1, ipAttribution=)]
    2019-03-23 fusion
  3. [GetPortalCommentsPageByObjectIdResponse(id=1955408, encodeId=17fb195540843, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 31 01:06:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697822, encodeId=3f6c169e82228, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Mar 23 20:06:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308859, encodeId=5c6b13088599e, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Dec 22 11:06:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355961, encodeId=4003355961bd, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Thu Dec 20 22:46:12 CST 2018, time=2018-12-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1955408, encodeId=17fb195540843, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 31 01:06:00 CST 2019, time=2019-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697822, encodeId=3f6c169e82228, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Mar 23 20:06:00 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308859, encodeId=5c6b13088599e, content=<a href='/topic/show?id=aa7291842d9' target=_blank style='color:#2F92EE;'>#误区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91842, encryptionId=aa7291842d9, topicName=误区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Dec 22 11:06:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=355961, encodeId=4003355961bd, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/AicRibibwhnWAW33YRia7y5sicGOoEzFQ4Jzmt3N9mtq1lZOXghRysQ33pzibKOXyQUuTpZSGsEeyicy1zX75nRB1yuaQ/132, createdBy=5e942360447, createdName=foxv3羽翼, createdTime=Thu Dec 20 22:46:12 CST 2018, time=2018-12-20, status=1, ipAttribution=)]
    2018-12-20 foxv3羽翼

    谢谢分享,学习了

    0

相关资讯

Lancet haemat:肿瘤相关静脉血栓风险的临床预测模型

静脉血栓是癌症的一种常见并发症,但静脉血栓形成的风险因人而异,取决于多种因素,包括癌症类型。Ingrid Pabinger等研究人员尝试开发一种用于预测癌症相关静脉血栓风险的临床模型,并进行外部验证。研究人员利用前瞻性研究——维也纳癌症和血栓研究(CATS)队列(1423位患者)的数据建立预测模型。然后在另一个相似的前瞻性多国家研究队列(MICA,832位患者)中验证该模型。此外,研究人员计算C指

肿瘤患者需警惕静脉血栓栓塞症

静脉血栓栓塞症(VTE)包括深静脉血栓(DVT)与肺栓塞(PE),已成为住院肿瘤患者死亡的第二大原因,仅次于肿瘤本身,堪称肿瘤患者的定时炸弹。肿瘤患者如果发生静脉血栓栓塞症,不仅增加治疗难度,降低患者的生活质量,减少生存预期,还会大幅增加住院时间与治疗费用。

Circulation:D-二聚体水平可预测冠心病患者的长期死亡率、心血管事件和癌症发病率

D-二聚体是交联纤维蛋白的降解产物,是高凝和血栓形成的标志物。D-二聚体中度升高与血管疾病患者的动静脉事件的风险相关。现研究人员对D-二聚体水平用于预测长期血管预后、特殊原因的死亡率以及新发癌症的作用进行评估。LIPID试验,将心肌梗死或不稳定心绞痛发生后5-38个月的患者随机分至普伐他汀(40mg/d)或安慰剂组。于起始和1年时检测D-二聚体水平。中位随访6.0年,总起来16年。7863位患者按

Neurocrit Care:长程局部溶栓术治疗脑静脉血栓形成

2018年8月来自美国的Adnan I. Qureshi等在Neurocritical Care上公布了他们的研究结果,探讨了血管内治疗无效的脑静脉血栓形成患者采用长程微导管局部溶栓术的疗效。

EUR Heart J:既往静脉血栓形成患者,瑞舒伐他汀对改善凝血有帮助?

2018年5月,发表于《Eur Heart J》上的一项研究,表明瑞舒伐他汀可改善静脉血栓形成(VT)患者的凝血指标。

Stroke:DVT/PE:DOACs的优越性再添一项 ICH显著降低

静脉血栓栓塞症(VTE),包括深静脉血栓形成(DVT)、肺栓塞(PE)等,严重影响患者生存率。抗凝药是重要的治疗选择。长期以来,华法林一直是标准的抗凝治疗药物。

Baidu
map
Baidu
map
Baidu
map